Concurrent offerings of stock and convertible notes are expected to bring Onyx Pharmaceuticals Inc. as much as $310.3 million in net proceeds - $356.9 million if underwriters opt to buy more shares and notes - as the firm looks to expand its pipeline offerings beyond the cancer drug partnered with Bayer HealthCare Pharmaceuticals Corp. (BioWorld Today) Read More
